GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » LifeTech Scientific Corp (HKSE:01302) » Definitions » Valuation Rank

LifeTech Scientific (HKSE:01302) Valuation Rank


View and export this data going back to 2011. Start your Free Trial

What is LifeTech Scientific Valuation Rank?

The Valuation Rank measures the current valuation of a business relative to other companies in the same industry and its own historical valuation. The companies are split in equal numbers and then ranked from 1 to 10, with 10 as the most undervalued and 1 as the most overvalued.

  1. Three factors:
    • Absolute valuation (medpsvalue) relative to current stock price, rank among all companies
    • Historical valuation over the past 10 years. Rank pe, ps, pocf, ev2ebit over their own historical values
    • Industry relative valuation
  2. Companies without enough data is not ranked
  3. Companies with negative earnings are ranked lower

These three factors are used to calculate the value score for every eligible company, with values from 1 to 10. The final ranked companies are split in equal numbers and ranked from 1 to 10, with 10 as the most undervalued, and 1 as the most overvalued. The numbers of companies in each rank are the same.


LifeTech Scientific Valuation Rank Related Terms

Thank you for viewing the detailed overview of LifeTech Scientific's Valuation Rank provided by GuruFocus.com. Please click on the following links to see related term pages.


LifeTech Scientific (HKSE:01302) Business Description

Traded in Other Exchanges
N/A
Address
No. 22, Keji 12th Road South, LifeTech Scientific Building, High-tech Industrial Park, Nanshan District, Shenzhen, CHN, 518063
LifeTech Scientific Corp develops and manufactures minimally invasive medical devices for cardiovascular and vascular diseases. The firm operates in three areas: Structural heart diseases business; Peripheral vascular diseases business and Cardiac pacing and electrophysiology business. It generates maximum revenue from the Peripheral vascular diseases business segment. Geographically, it derives a majority of revenue from China.
Executives
Xie Yuehui 2201 Interest of corporation controlled by you
Xianjian Advanced Technology Limited 2101 Beneficial owner
Hhlr Advisors, Ltd. 2102 Investment manager
Bank Of Communications Trustee Limited 2301 Trustee
Xie Yuehui 2201 Interest of corporation controlled by you
Hhlr Fund, L.p. 2101 Beneficial owner
Hillhouse Capital Advisors, Ltd. 2102 Investment manager
Gaoling Fund, L.p. 2101 Beneficial owner